ELUTIA INC. (ELUT) Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Elutia Inc NASDAQ:ELUT Healthcare · Biotechnology
Mkt Cap $37.07M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Elutia (Nasdaq: ELUT) announced it will release third quarter 2026 financial results after market close on Thursday, November 5, 2026.
Management will host a conference call and webcast at 5:00 p.m. ET that same day, with registration required for dial-in access and an archived webcast available on the company's investor relations site.
This is a routine scheduling notice with no results or guidance — investors should watch for the actual release on November 5.
• 10d ago AI analysis › Press Release ⚠ 2
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million indemnity holdback to Elutia with no claims, completing the $88 million BioEnvelope divestiture that closed October 1, 2025.
Elutia says this is the third of three 2026 funding milestones, alongside the Avenue Capital loan facility (closed August 11) and SimpliDerm divestiture (closed August 17), and that it is now funded into 2029 without an equity offering.
For Boston Scientific, the input filer, this is a routine escrow release with no material financial impact; the substantive upside belongs to Elutia, which expects an FDA clearance decision for NXT-41x in the first half of 2027.
• 1mo ago AI analysis › Press Release
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
Elutia announced that CEO Dr. Randy Mills, CSO Dr. Michelle Williams, and CFO Matthew Ferguson will present at the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel on September 15-16, 2026.
The live presentation begins at 4:30 pm Eastern Time on Tuesday, September 15, and replaces the previously announced pre-recorded presentation; management will also host one-on-one investor meetings over both days.
The talk will focus on Elutia's drug-eluting biomatrix technology aimed at addressing post-surgical infection in plastic and reconstructive surgeries, but the release contains no new financial or clinical data.
• 1mo ago AI analysis › Press Release
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
Elutia announced that CEO Dr. Randy Mills, CFO Matthew Ferguson, and Chief Scientific Officer Dr. Michelle Williams will participate in two September investor conferences.
The company will host one-on-one meetings at the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference in New York on September 10, 2026, and will present and host meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 15-16, 2026.
Management's H.C. Wainwright presentation will focus on Elutia's drug-eluting biomatrix technology aimed at reducing post-surgical infection in plastic and reconstructive surgeries; the presentation will be available on-demand via webcast.
• 1mo ago AI analysis › Press Release ⚠ 1
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
Elutia Inc. has completed the sale of its SimpliDerm hydrated human acellular dermal matrix (ADM) business to Cellution Biologics.
The transaction terms include US$8 million payable at closing, subject to adjustments, and up to US$3 million in potential milestone payments over the next 18 months.
SimpliDerm was an established product in the U.S. reconstructive surgery market with a proven commercial presence.
• 2mo ago AI analysis › Press Release
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Elutia completed the sale of its SimpliDerm business to Cellution Biologics for total consideration of up to $11 million, receiving $8 million in cash at closing.
The non-dilutive proceeds extend the company's financial runway, which now covers operations through the first full year of the NXT-41x commercial launch in 2028.
NXT-41x is an antibiotic-eluting biomatrix targeting post-operative infections, with FDA clearance expected in the first half of 2027 for the $1.5 billion U.S. plastic and reconstructive surgery market.
• 2mo ago AI analysis › Press Release ● Major
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Elutia secured up to $26 million in non-dilutive capital through a credit facility and the SimpliDerm divestiture, fully funding the company through the anticipated commercial launch of NXT-41x.
Q2 revenue was $2.4 million, with GAAP gross margin expanding to 59.6% and adjusted gross margin reaching 70.7%, while net loss narrowed to $7.6 million compared to the prior year.
Regulatory timelines remain on track, with an FDA clearance decision for NXT-41 expected in 4Q 2026 and for NXT-41x in 1H 2027, supported by strong surgeon demand data.
• 2mo ago AI analysis › Press Release ⚠ 2
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
Elutia secured a $15 million loan financing from Avenue Capital Group, with $10 million funded at closing and a $5 million tranche contingent on FDA 510(k) clearance of NXT-41x.
The non-dilutive capital strengthens the balance sheet and funds the commercialization of the next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgeries.
FDA clearance for NXT-41x is anticipated in the first half of 2027, targeting a $1.5 billion U.S. market opportunity where post-operative infection rates range from 15–20%.
• 2mo ago AI analysis › Press Release
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Elutia announced that it will release its second quarter 2026 financial results after market close on Thursday, August 13, 2026.
Management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the results.
Investors can access the live and archived webcast via the Investors section of the Elutia website.
• 3mo ago AI analysis › Press Release
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia signed a definitive agreement to sell its SimpliDerm business to Cellution Biologics Inc. for total consideration of up to $11 million, consisting of $8 million in cash at closing and up to $3 million in milestone payments.
The divestiture strengthens Elutia’s balance sheet with non-dilutive capital intended to advance its lead asset, NXT-41x, toward a targeted commercial launch in 2027.
By exiting the SimpliDerm business, Elutia sharpens its strategic focus on the $1.5 billion plastic and reconstructive surgery market opportunity for its drug-eluting biomatrix technology.
• 3mo ago AI analysis › Press Release
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
Elutia announced that CEO Dr. Randy Mills and CSO Dr. Michelle Williams will present at the Planet MicroCap Showcase 2026 in Las Vegas on June 17-18, 2026.
The presentation will focus on the company's drug-eluting biomatrix technology aimed at reducing post-surgical infection in implant-based breast reconstruction.
Elutia will also host one-on-one investor meetings during the event, accessible via registration on the Planet MicroCap website.
• 4mo ago AI analysis › Press Release ⚠ 4
A Reno Biotech Just Rang the Nasdaq Bell · Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
Conexeu Sciences (CNXU) is the subject of a paid promotional article published by Market IQ Media Group, highlighting its recent Nasdaq listing and preclinical regenerative medicine platform.
The article reiterates that Conexeu holds full IP rights to its CXU platform and plans a 510(k) submission in early 2027, but contains no new material disclosures or financial results from the company itself.
It frames Conexeu within a broader 'regenerative medicine' thesis, comparing it to peers like Pacira (PCRX), Stratasys (SSYS), Smith & Nephew (SNN), and Elutia (ELUT), while explicitly disclosing a conflict of interest due to advertising fees paid by Conexeu's marketing group.
• 5mo ago AI analysis › Press Release
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Elutia granted 48,000 non-qualified stock options to one new employee as an inducement award.
The options carry an exercise price of $1.05, matching the closing stock price on the grant date of May 13, 2026.
The award was approved by the Compensation Committee and complies with Nasdaq Listing Rule 5635(c)(4), vesting over four years.
• 5mo ago AI analysis › Press Release ⚠ 3
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
Elutia reported Q1 2026 revenue of $3.1 million, a 6% year-over-year increase, with GAAP gross margin expanding to 57.9% from 46.8% a year earlier.
The company highlighted progress on its NXT-41 510(k) submission, with FDA clearance anticipated in Q4 2026, and NXT-41x clearance expected in H1 2027. New automated manufacturing processes are online, supporting a gross margin target of over 80% at scale.
Elutia ended the quarter with $28.5 million in cash and $8.0 million in escrow, totaling $36.5 million in liquidity. The company is also exploring strategic options for its SimpliDerm and Cardiovascular product lines.
• 5mo ago AI analysis › Press Release
Elutia to Present at the 16th Annual LD Micro Invitational May 18th
Elutia announced that CEO Randy Mills and CFO Matt Ferguson will present at the 16th Annual LD Micro Invitational on May 18, 2026.
The presentation will focus on the company's drug-eluting biomatrix technology aimed at reducing post-surgical infections in implant-based breast reconstruction.
One-on-one investor meetings will be available during the event, which is hosted by LD Micro, a subsidiary of Freedom US Markets.
• 5mo ago AI analysis › Press Release
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
Elutia announced that CEO Randy Mills and CFO Matt Ferguson will present at the 16th Annual LD Micro Invitational on May 18, 2026.
The presentation will focus on the company's drug-eluting biomatrix technology for implant-based breast reconstruction, specifically addressing post-surgical infection risks.
One-on-one investor meetings will be available during the event in Los Angeles.
• 5mo ago AI analysis › Press Release ● Major
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
globenewswire.com • 6mo ago Press Release
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
globenewswire.com • 7mo ago 
